human | Q5 |
P496 | ORCID iD | 0000-0001-5288-0394 |
P69 | educated at | University of Toronto | Q180865 |
P108 | employer | McMaster University | Q632891 |
P735 | given name | James | Q677191 |
James | Q677191 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q22241393 | 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. |
Q84583277 | 2009 evidence-based clinical practice guidelines for diagnosing a first episode of lower extremities deep vein thrombosis in ambulatory outpatients |
Q52687892 | 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. |
Q93160371 | 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer |
Q91665029 | 2019 international clinical practice guidelines for the treatment of venous thromboembolism - Authors' reply |
Q88379572 | 4 risk assessment models had good calibration but poor discrimination for VTE in hospitalized medical patients |
Q92822026 | A Device on Trial - Intermittent Pneumatic Compression in Critical Care |
Q44588720 | A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome |
Q55401173 | A pharmacist checklist for direct oral anticoagulant management: Raising the bar. |
Q49170958 | A randomized trial of diagnostic strategies after normal proximal vein ultrasonography for suspected deep venous thrombosis: D-dimer testing compared with repeated ultrasonography |
Q38180352 | ACP Journal Club. Review: new oral factor Xa inhibitors reduce DVT compared with standard thromboprophylaxis after THR or TKR. |
Q51359881 | Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study. |
Q91004451 | Accuracy of age-adjusted D-dimer to rule out deep vein thrombosis in the elderly |
Q51541136 | Accuracy of emergency physician-performed ultrasonography in the diagnosis of deep-vein thrombosis: a systematic review and meta-analysis. |
Q93097266 | An assay to measure levels of factor Xa inhibitors in blood and plasma |
Q49168829 | An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial |
Q50751904 | Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. |
Q50277147 | Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery. |
Q36323517 | Anticoagulant prophylaxis in special populations with an indwelling epidural catheter or renal insufficiency |
Q52680907 | Antiphospholipid Antibodies and Recurrent Thrombosis after a First Unprovoked Venous Thromboembolism. |
Q34497581 | Approach to the new oral anticoagulants in family practice: part 1: comparing the options. |
Q34666269 | Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions |
Q94355271 | Approche à l’égard des nouveaux anticoagulants oraux en pratique familiale: 1 partie : Comparer les options |
Q94355279 | Approche à l’égard des nouveaux anticoagulants oraux en pratique familiale: 2 partie : Répondre aux questions souvent posées |
Q34466253 | Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. |
Q34421159 | Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials |
Q82264026 | Barriers and potential solutions toward optimal prophylaxis against deep vein thrombosis for hospitalized medical patients: a survey of healthcare professionals |
Q91813216 | Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time |
Q37555975 | Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency |
Q38502463 | Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures |
Q38961424 | Bridge Therapy Outcomes in Patients With Mechanical Heart Valves |
Q87023752 | Bridging Anticoagulation in Patients with Atrial Fibrillation |
Q81438697 | Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery |
Q94554773 | Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events |
Q115212685 | Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020 |
Q33936106 | Canadian guidelines for body weight classification in adults: application in clinical practice to screen for overweight and obesity and to assess disease risk |
Q112571556 | Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort |
Q38633455 | Catheter-directed thrombolysis for extensive iliofemoral deep vein thrombosis: review of literature and ongoing trials |
Q47598845 | Cerebral Oximetry Monitoring to Maintain Normal Cerebral Oxygen Saturation during High-risk Cardiac Surgery: A Randomized Controlled Feasibility Trial |
Q47351547 | Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis |
Q38117418 | Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications |
Q28218081 | Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials |
Q37633435 | Combined warfarin-aspirin therapy: what is the evidence for benefit and harm and which patients should (and should not) receive it? |
Q28196728 | Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding |
Q34570274 | Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism |
Q39874027 | Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: a randomized trial |
Q38979421 | Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism |
Q50595629 | D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. |
Q80103481 | DHCR7 mutation carrier rates and prevalence of the RSH/Smith-Lemli-Opitz syndrome: where are the patients? |
Q37806823 | Deep vein thrombosis prophylaxis in hospitalized medical patients: current recommendations, general rates of implementation, and initiatives for improvement |
Q92473717 | Deep vein thrombosis: update on diagnosis and management |
Q37400267 | Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. |
Q37687290 | Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. |
Q43676087 | Detection of pulmonary emboli with 99mTc-labeled anti-D-dimer (DI-80B3)Fab' fragments (ThromboView). |
Q38293749 | Direct oral anticoagulants: new drugs and new concepts |
Q51938849 | Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. |
Q35769983 | Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome |
Q100304837 | Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study |
Q92297860 | Effectiveness of interventions for the implementation of thromboprophylaxis in hospitalised patients at risk of venous thromboembolism: an updated abridged Cochrane systematic review and meta-analysis of randomised controlled trials |
Q43849809 | Elevated cardiac troponin levels in patients with submassive pulmonary embolism |
Q89502763 | Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant-Reply |
Q24248057 | Epidural analgesia for pain relief following hip or knee replacement |
Q91452045 | Erratum to: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant who Need an Elective Surgery or Procedure: Design and Rationale |
Q92340268 | Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients |
Q64115894 | Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill |
Q84059927 | Evidence and clinical judgment: Treatment of cerebral vein thrombosis |
Q39024214 | Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials |
Q84207461 | Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism |
Q34293031 | Factors that predict thrombosis in relatives of patients with venous thromboembolism |
Q38131631 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. |
Q28077943 | Guidance for the evaluation and treatment of hereditary and acquired thrombophilia |
Q33351141 | Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials |
Q36225567 | Hormone replacement therapy and risk for venous thromboembolism: what's new and how do these findings influence clinical practice? |
Q38038988 | How I treat anticoagulated patients undergoing an elective procedure or surgery |
Q85488740 | How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadi |
Q97540717 | Human important outcomes and EBM during the COVID-19 pandemic |
Q43739758 | Incidence of Smith-Lemli-Opitz syndrome in Canada: results of three-year population surveillance |
Q80842657 | Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer |
Q46381164 | Influence of warfarin on symptoms of fatigue: findings of a randomized trial |
Q38081938 | Initial and long-term treatment of deep venous thrombosis: recent clinical trials and their impact on patient management. |
Q91461735 | International Delphi survey of the ESTS/AATS/ISTH task force on venous thromboembolism prophylaxis in thoracic surgery: the role of extended post-discharge prophylaxis |
Q38979052 | International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer |
Q57634203 | Interruption of Warfarin Anticoagulation for Dental Surgery: Response |
Q53403458 | Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism. |
Q54327928 | Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials. |
Q91593983 | Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study |
Q80020433 | Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin |
Q55256572 | Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial. |
Q36199228 | Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency |
Q100404480 | Management of Antithrombotic Therapy After Gastrointestinal Bleeding: A Mixed Methods Study of Healthcare Providers |
Q90850119 | Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group |
Q38049617 | Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach |
Q36255407 | Management of hypertension in overweight and obese patients: a practical guide for clinicians |
Q96436479 | Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasi |
Q27000446 | Management of patients who are receiving warfarin or a new oral anticoagulant and require urgent or emergency surgery |
Q36718482 | Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach |
Q39079521 | Managing challenging patients with venous thromboembolism: a practical, case-based approach |
Q34575893 | Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients |
Q46960763 | Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes |
Q87015681 | New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction? |
Q36169479 | Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction |
Q34145130 | Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial |
Q45218778 | Oral vitamin K produces a normal INR within 24 hours of its administration in most patients discontinuing warfarin |
Q34388837 | Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention o |
Q37389225 | Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study |
Q45040639 | Patient preferences for capillary vs. venous INR determination in an anticoagulation clinic: a randomized controlled trial |
Q43691261 | Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences |
Q34144428 | Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism |
Q88558609 | Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial |
Q38405653 | Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials |
Q37062044 | Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation |
Q87294444 | Perioperative Management of Dabigatran: A Prospective Cohort Study |
Q92413106 | Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant |
Q38956544 | Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review |
Q46426278 | Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice. |
Q35066069 | Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians |
Q92649036 | Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines |
Q53671515 | Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. |
Q47215248 | Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). |
Q92983756 | Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis |
Q90480584 | Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis |
Q50021309 | Perioperative management of anticoagulant and antiplatelet therapy. |
Q38127571 | Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines |
Q35752584 | Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q38049284 | Perioperative management of patients having noncardiac surgery who are receiving anticoagulant or antiplatelet therapy: an evidence-based but practical approach |
Q38117546 | Perioperative management of patients who are receiving a novel oral anticoagulant. |
Q90694832 | Perioperative management of patients who are receiving antiplatelet therapy: a case-based, evidence-informed approach |
Q38735858 | Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines |
Q37634168 | Periprocedural anticoagulation practices in warfarin-treated patients who require elective angiography with or without percutaneous coronary intervention: a retrospective chart review |
Q38469560 | Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial |
Q26992141 | Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates |
Q91640557 | Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes |
Q34623665 | Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management |
Q53783646 | Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment? |
Q38077891 | Portal vein thrombosis: a clinician-oriented and practical review |
Q41018778 | Postdischarge venous thromboembolic complications following pulmonary oncologic resection: An underdetected problem |
Q37636907 | Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey |
Q99618868 | Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study |
Q99608096 | Predictors of oral anticoagulant-associated adverse events in seniors transitioning from hospital to home: a retrospective cohort study protocol |
Q48539705 | Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial |
Q98212318 | Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure |
Q33528393 | Preventing venous thromboembolism in long-term care residents: Cautious advice based on limited data |
Q37554147 | Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment |
Q34609335 | Prevention of overweight and obesity in adult populations: a systematic review |
Q33418678 | Prevention of venous thromboembolism in the Enhanced Recovery After Surgery (ERAS) setting: an evidence-based review |
Q50143690 | Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. |
Q28293377 | Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study |
Q60568634 | Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal |
Q92875389 | Pulmonary embolism: update on diagnosis and management |
Q54221917 | Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. |
Q100453671 | Recommandations canadiennes pour les pratiques optimales de soins de l’AVC, septième édition : l’acide acétylsalicylique pour la prévention d’événements vasculaires |
Q88400665 | Reply to Dr Lessire et al |
Q94364706 | Response |
Q95357434 | Response |
Q44772937 | Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”. |
Q49970899 | Reversal agents for non-vitamin K antagonist oral anticoagulants. |
Q34807799 | Review: postmenopausal estrogen replacement therapy increases the risk for venous thromboembolism. |
Q34621398 | Review: stress hyperglycemia after ischemic stroke indicates a greater risk for death in patients without diabetes. |
Q37075924 | Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism |
Q34096312 | Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis |
Q34603112 | Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis |
Q93013958 | Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery |
Q87420653 | Ruling out DVT using the Wells rule and a D-dimer test |
Q37398262 | Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis |
Q37740734 | Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis |
Q36659789 | Safety of withholding anticoagulation in pregnant women with suspected deep vein thrombosis following negative serial compression ultrasound and iliac vein imaging. |
Q95850080 | Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19 |
Q92765018 | Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-sp |
Q41653423 | Screening for Occult Cancer in Unprovoked Venous Thromboembolism |
Q85705712 | Secondary prevention of venous thromboembolism |
Q51838214 | Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. |
Q74387197 | Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes |
Q50946976 | Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. |
Q37946869 | Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. |
Q36541962 | Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. |
Q34130081 | Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review |
Q34420870 | Systematic overview of warfarin and its drug and food interactions |
Q37288236 | Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism |
Q33388230 | The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients |
Q50048381 | The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. |
Q84502291 | The association between venous thromboembolism and physical inactivity in everyday life |
Q33489383 | The devil is in the details...or not? A primer on individual patient data meta-analysis |
Q36323507 | The diagnosis of deep venous thrombosis and pulmonary embolism in medical-surgical intensive care unit patients |
Q35732010 | The management of hypertension in the overweight and obese patient: is weight reduction sufficient? |
Q33346026 | The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). |
Q45298422 | The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism |
Q80214015 | The safety of co-administered continuous epidural analgesia and low-molecular-weight heparin after major orthopedic surgery: assessment of a standardized patient management protocol |
Q37860662 | The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary |
Q37884681 | The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines |
Q51826400 | Thromboprophylaxis for hospitalized medical patients: a multicenter qualitative study. |
Q34609349 | Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis |
Q36063745 | Treatment of deep vein thrombosis: what factors determine appropriate treatment? |
Q42652908 | Unusual venous thrombosis |
Q40887178 | Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial |
Q37325204 | Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials |
Q36748915 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors |
Q92300533 | Venous thromboembolism prophylaxis in thoracic surgery patients: an international survey |
Search more.